Cutaneous manifestations in familial hypercholesterolaemia. (September 2021)

• Record Type: Journal Article
• Authors: Katzmann, Julius L.; Lehmann, Maximilian; Tünnemann-Tarr, Adrienn; an Haack, Ira; Dressel, Alexander; März, Winfried; Laufs, Ulrich
• Is Part Of: Atherosclerosis. Volume 333(2021)
• Page Start: 116
• Page End: 123
• Publication Date: 2021-09
• Subjects: LDL cholesterol -- Screening -- Diagnosis -- Statin -- LDL receptor -- Genetic; Arteriosclerosis -- Periodicals; Electronic journals; 616.136
• DOI: 10.1016/j.atherosclerosis.2021.07.007
• Languages: English
• ISSNs: 0021-9150

Abstract

Abstract: Background and aims: Familial hypercholesterolaemia (FH) is associated with high cardiovascular risk and underdiagnosed. Cutaneous manifestations are traditionally used as a major criterion of FH. They are included in the Dutch Lipid Clinic Network or Simon Broome registry criteria. The objective of this study was to evaluate cutaneous manifestations in contemporary FH patients. Methods: We prospectively analysed the clinical presentation of FH patients referred to a University lipid clinic and validated these data in the German FH registry CaRe High. Results: Physical examination revealed that only 14.4% of the FH patients in the lipid clinic cohort (n = 223) showed cutaneous manifestations. An arcus cornealis was present in 0.9%, xanthomata in 1.8%, and xanthelasmata in 12.1%. Xanthelasmata are not part of the clinical scores, but represented 84.4% of all cutaneous manifestations. In 42.6% (n = 95) of the patients, genetic analysis was available. A causal FH mutation was detected in 50.5%. Among carriers, 66.7% had no cutaneous manifestation, 8.3% exhibited an arcus cornealis or xanthomata, and 25.0% had xanthelasmata. In the CaRe High FH registry, data on cutaneous manifestations were available in n = 1274 patients. 3.5% had xanthomata, 5.7% an arcus cornealis, and 7.7% at least one of both; xanthelasmata were present in 10.3%. Conclusions: Cutaneous manifestations are only present in a minority of contemporary patients with FH including the subgroup with monogenic FH mutations. Although rare, the cutaneous signs have value in terms of specificity. However, the clinical characteristics shared by the majority of FH patients may be better suited for screening purposes. Graphical abstract: Image 1 Highlights: Diagnosis of familial hypercholesterolaemia (FH) includes cutaneous manifestations. Prevalence of cutaneous manifestations (arcus cornealis, xanthomata) is unknown. Main finding: Cutaneous manifestations are rare (6.9% of ~1500 FH patients). Xanthelasmata most common, but not included in diagnostic scores for FH. Currently recommended FH scores may not be optimal for screening.